Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Recruiting

Phase 3

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Sponsor:

Pharvaris Netherlands B.V.

Code:

NCT06343779

Conditions

Hereditary Angioedema

Hereditary Angioedema Type I

Hereditary Angioedema Type II

Hereditary Angioedema Types I and II

Hereditary Angioedema Attack

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Deucrictibant, Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Pharvaris Netherlands B.V. on 2025-04-20.